Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $30
Solid Biosciences said Tuesday that the first three patients to receive its experimental gene therapy for Duchenne muscular dystrophy all produced high levels of microdystrophin,
A strange thing happened weeks before the Food and Drug Administration approved the first treatment made with CRISPR gene editing, an all-but cure for certain
United Therapeutics said Monday that the Food and Drug Administration has cleared it to begin the first clinical trial testing whether organs from gene-edited pigs
Jens Kuhn wasn’t surprised people accused him, mockingly, of doing drugs. He’s used to hate mail. After all, he has the most despised job in
Scribe Therapeutics has laid off just under 20% of its staff, the company confirmed to STAT on Wednesday, joining a slate of CRISPR gene editing
In 2013, Google announced it would attempt to understand and ultimately slow aging through a company called Calico, a moonshot effort that would absorb at
Pfizer has abandoned development of a hemophilia A gene therapy it licensed from Sangamo Therapeutics, a move that could imperil Sangamo’s future. It’s a sudden
In her years-long effort to develop a gene therapy for her 7-year-old son Maxwell, Amber Freed has tried most of the usual fundraising tricks: A
Editas Medicine said Thursday afternoon it will lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program